Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
Metagenomi Therapeutics, an in vivo genome editing company, announced that its President and CEO will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference. The company focuses on developing proprietary CRISPR-based genetic medicines, with a lead program targeting hemophilia A showing promising preclinical results.